Thumbnail Image
Item

Management of patients with advanced prostate cancer. Report from the 2024 advanced prostate cancer consensus conference (APCCC)

Gillessen, Silke
; 
Turco, Fabio
; 
Davis, Ian D.
; 
Efstathiou, Jason
; 
Fizazi, Karim
; 
James, Nicholas D.
; 
Shore, Neal
; 
Small, Eric
; 
Smith, Matthew
; 
Sweeney, Christopher
... show 10 more
Authors
Gillessen, Silke
 Turco, Fabio
 Davis, Ian D.
 Efstathiou, Jason
 Fizazi, Karim
 James, Nicholas D.
 Shore, Neal
 Small, Eric
 Smith, Matthew
 Sweeney, Christopher
 Tombal, Bertrand
 Zilli, Thomas
 Agarwal, Neeraj
 Antonarakis, Emmanuel S.
 Aparicio, Ana M.
 Armstrong, Andrew J.
 Bastos, Diogo Assed
 Attard, Gerhardt
 Axcrona, Karol
 Ayadi, Mouna
 Beltran, Himisha
 Bjartell, Anders
 Blanchard, Pierre
 Bourlon, Maria T.
 Briganti, Alberto
 Bulbul, Muhammad
 Buttigliero, Consuelo
 Caffo, Orazio
 Castellano, Daniel
 Castro, Elena
 Cheng, Heather H.
 Chi, Kim N.
 Clarke, Caroline S.
 Clarke, Noel W.
 de Bono, Johann S.
 De Santis, Maria
 Duran, Ignacio
 Efstathiou, Eleni
 Ekeke, Onyeanunam
 El Nahas, Tamer I.H.
 Emmett, Louise
 Fanti, Stefano
 Fatiregun, Omolara A.
 Feng, Felix Y.
 Fong, Peter C.C.
 Fonteyne, Valerie
 Fossati, Nicola
 George, Daniel
 Gleave, Martin
 Gravis, Gwenaelle
 Halabi, Susan
 Heinrich, Daniel
 Herrmann, Ken
 Hofman, Michael S.
 Hope, Thomas A.
 Horvath, Lisa G.
 Hussain, Maha
 Jereczek-Fossa, Barbara Alicja
 Jones, Robert J.
 Joshua, Anthony M.
 Kanesvaran, Ravindran
 Keizman, Daniel
 Khauli, Raja B.
 Kramer, Gero
 Loeb, Stacy
 Mahal, Brandon A.
 Maluf, Fernando
 Mateo, Joaquin
 Matheson, David
 Matikainen, Mika P.
 McDermott, Ray
 McKay, Rana R.
 Mehra, Niven
 Merseburger, Axel
 Morgans, Alicia K.
 Morris, Michael J.
 Mrabti, Hind
 Mukherji, Deborah
 Murphy, Declan G.
 Murthy, Vedang
 Mutambirwa, Shingai B.A.
 Nguyen, Paul L.
 Oh, William K.
 Ost, Piet
 O’Sullivan, Joe M.
 Padhani, Anwar R.
 Parker, Chris C.
 Poon, Darren M.C.
 Pritchard, Colin C.
 Rabah, Danny M.
 Rathkopf, Dana
 Reiter, Robert E.
 Renard-Penna, Raphaele
 Ryan, Charles J.
 Saad, Fred
 Sade, Juan Pablo
 Sandhu, Shahneen
 Sartor, Oliver A.
 Schaeffer, Edward
 Scher, Howard I.
 Sharifi, Nima
 Skoneczna, Iwona
 Soule, Howard
 Spratt, Daniel E.
 Srinivas, Sandy
 Sternberg, Cora N.
 Suzuki, Hiroyoshi
 Taplin, Mary-Ellen
 Thellenberg-Karlsson, Camilla
 Tilki, Derya
 Türkeri, Levent
 Uemura, Hiroji
 Ürün, Yüksel
 Vale, Claire L.
 Vapiwala, Neha
 Walz, Jochen
 Yamoah, Kosj
 Ye, Dingwei
 Yu, Evan Y.
 Zapatero, Almudena
 Omlin, Aurelius
Editors
Other contributors
Affiliation
Epub Date
Issue Date
2024-10-11
Submitted date
Subjects
adjuvant therapy
 biochemical recurrence
 bone protection
 genetics and genomics
 hormonal treatment
 next-generation imaging
 positron emission tomography
 prostate cancer
 prostate-specific membrane antigen
 salvage therapy
Show all metadata
Files
Thumbnail Image
1-s2.0-S0302283824026101-main.pdf
Adobe PDF, 1.51 MB
Alternative
Abstract
BACKGROUND AND OBJECTIVE: Innovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that greatly impact daily practice. The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) surveyed experts on key questions in clinical management in order to supplement evidence-based guidelines. Here we present voting results for questions from APCCC 2024. METHODS: Before the conference, a panel of 120 international PC experts used a modified Delphi process to develop 183 multiple-choice consensus questions on eight different topics. Before the conference, these questions were administered via a web-based survey to the voting panel members ("panellists"). KEY FINDINGS AND LIMITATIONS: Consensus was a priori defined as ≥75% agreement, with strong consensus defined as ≥90% agreement. The voting results show varying degrees of consensus, as discussed in this article and detailed in the Supplementary material. These findings do not include a formal literature review or meta-analysis. CONCLUSIONS AND CLINICAL IMPLICATIONS: The voting results can help physicians and patients navigate controversial areas of clinical management for which high-level evidence is scant or conflicting. The findings can also help funders and policymakers in prioritising areas for future research. Diagnostic and treatment decisions should always be individualised on the basis of patient and cancer characteristics, and should incorporate current and emerging clinical evidence, guidelines, and logistic and economic factors. Enrolment in clinical trials is always strongly encouraged. Importantly, APCCC 2024 once again identified important gaps (areas of nonconsensus) that merit evaluation in specifically designed trials.
Citation
Gillessen, S., Turco, F., Davis, I.D. et al. (2024) Management of patients with advanced prostate cancer. Report from the 2024 advanced prostate cancer consensus conference (APCCC). European Urology, 87 (2), pp. 157-216. https://doi.org/10.1016/j.eururo.2024.09.017
Publisher
Elsevier
Journal
European Urology
Research Unit
URI
http://hdl.handle.net/2436/625739
DOI
10.1016/j.eururo.2024.09.017
PubMed ID
PubMed Central ID
Embedded videos
Additional Links
https://doi.org/10.1016/j.eururo.2024.09.017
Type
Journal article
Language
en
Description
© 2024 The Authors. Published by Elsevier. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: https://doi.org/10.1016/j.eururo.2024.09.017
Series/Report no.
ISSN
0302-2838
EISSN
1873-7560
ISBN
ISMN
Gov't Doc #
Sponsors
Rights
Research Projects
Organizational Units
Journal Issue
Embedded videos
Collections
Faculty of Education, Health and Wellbeing